BioCorRx Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
BICXStored price and day change unavailable
Contents
Condensed Consolidated Balance Sheets
| September 30 | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $287,688 | $88,033 |
| Accounts receivable, net | 194,442 | - |
| Grant receivable | 761,515 | - |
| Inventory | 155,367 | - |
| Prepaid expenses | 63,164 | 29,963 |
| Total current assets | 1,462,176 | 117,996 |
| Property and equipment, net | 7,685 | 18,977 |
| Right to use assets | 169,443 | 199,184 |
| Other assets: | ||
| Intangible assets, net | 3,011,833 | 7,848 |
| Goodwill | 2,840,400 | - |
| Deposits, long term | 41,936 | 41,936 |
| Total other assets | 5,894,169 | 49,784 |
| Total assets | $7,533,473 | $385,941 |
| LIABILITIES AND DEFICIT | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses, including related party payables of $1,629,743 and $1,349,465, respectively | $12,400,939 | $5,574,831 |
| Deferred revenue-grant | 56,590 | 56,590 |
| Lease liability, short term | 41,686 | 40,057 |
| Notes payable, net of debt discount of $3,216 and $41,452 | 1,547,853 | 1,343,278 |
| Notes payable, related parties | 991,059 | 1,192,859 |
| Total current liabilities | 15,038,127 | 8,207,615 |
| Long term liabilities: | ||
| EIDL loan, long term | 69,803 | 71,029 |
| Upfront purchase price liability | 85,440 | - |
| Royalty liability | 317,577 | - |
| Royalty obligation, net of discount of $4,184,810 and $4,418,698, related parties | 4,659,064 | 4,303,402 |
| Lease liability, long term | 127,757 | 159,127 |
| Total liabilities | 20,297,768 | 12,741,173 |
| Commitments and contingencies | ||
| Deficit: | ||
| Preferred stock, no par value; 600,000 shares authorized at September 30, 2025 and December 31, 2024 | - | - |
| Series A convertible preferred stock, no par value; 80,000 designated; 80,000 shares issued and outstanding as of September 30, 2025 and December 31, 2024 | 16,000 | 16,000 |
| Series B convertible preferred stock, no par value; 160,000 designated; 160,000 shares issued and outstanding as of September 30, 2025 and December 31, 2024 | 5,616 | 5,616 |
| Common stock, $0.001 par value; 750,000,000 shares authorized, 20,188,029 and 13,299,349 shares issued and outstanding as of as of September 30, 2025 and December 31, 2024, respectively | 20,188 | 13,299 |
| Common stock subscribed | 100,000 | 100,000 |
| Additional paid in capital | 73,575,400 | 70,953,807 |
| Accumulated deficit | (87,201,843) | (83,209,142) |
| Total deficit attributable to BioCorRx, Inc. | (13,484,639) | (12,120,420) |
| Non-controlling interest | 720,344 | (234,812) |
| Total deficit | (12,764,295) | (12,355,232) |
| Total liabilities and deficit | $7,533,473 | $385,941 |
| See the accompanying notes to the unaudited condensed consolidated financial statements | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.